New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - roxithromycin 50mg - dispersible tablet - 50 mg - active: roxithromycin 50mg excipient: colloidal silicon dioxide crospovidone fumaric acid glycyrrhiza glabra macrogol 6000 magnesium stearate methacrylic acid copolymer microcrystalline cellulose purified talc saccharin sodium sodium hydroxide sodium laureth sulfate strawberry flavour triethyl citrate - rulide d 50mg tablets are indicated for the treatment of the following mild to moderately severe infections in children caused by, or likely to be caused by susceptible micro-organisms: - acute pharyngitis - acute tonsillitis - impetigo

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - roxithromycin, quantity: 300 mg - tablet, film coated - excipient ingredients: purified talc; hyprolose; propylene glycol; maize starch; magnesium stearate; povidone; glucose; poloxamer; titanium dioxide; hypromellose; colloidal anhydrous silica - for the treatment of mild to moderately severe infections in adults caused by or likely to be caused by susceptible micro-organisms: . acute pharyngitis, tonsillitis, sinusitis; . acute bronchitis and acute exacerbations of chronic bronchitis; community acquired pneumonia; . skin and skin structure infections; . non-gonoccocal urethritis. appropriate culture and sensitivity tests should be performed when necessary to determine organisms' susceptibility and thus treatment suitability. therapy with rulide may be initiated before results of these tests are known; once results become available, appropriate therapy should be considered.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - roxithromycin, quantity: 50 mg - tablet, dispersible - excipient ingredients: sodium lauryl sulfate; purified talc; fumaric acid; crospovidone; microcrystalline cellulose; methacrylic acid copolymer; colloidal anhydrous silica; triethyl citrate; macrogol 6000; saccharin sodium; sodium hydroxide; magnesium stearate; flavour - children: for the treatment of the following mild to moderately severe infections in children caused by or likely to be caused by susceptible micro-organisms: acute pharyngitis, acute tonsilitis and impetigo. appropriate culture and sensitivity tests should be performed when necessary to determine an organism's susceptibility and thus treatment suitability. therapy may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - roxithromycin, quantity: 150 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; hyprolose; purified talc; magnesium stearate; glucose; titanium dioxide; maize starch; povidone; poloxamer; propylene glycol; hypromellose - adults: for the treatment of mild to moderately severe infections in adults caused by or likely to be caused by susceptible micro-organisms in: acute pharyngitis; tonsillitis and sinusitis. acute bronchitis and acute exacerbations of chronic bronchitis; community acquired pneumonia (including atypical pneumonia). skin and soft tissue infections and non-gonococcal urethritis children: for the treatment of the following mild to moderately severe infections in children caused by or likely to be caused by susceptible micro-organisms: acute pharyngitis; acute tonsillitis; impetigo.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - roxithromycin -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - roxithromycin -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - roxithromycin -

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - roxithromycin 150mg - film coated tablet - 150 mg - active: roxithromycin 150mg excipient: colloidal silicon dioxide glucose hypromellose   magnesium stearate maize starch poloxamer povidone propylene glycol purified talc titanium dioxide

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - roxithromycin 300mg - film coated tablet - 300 mg - active: roxithromycin 300mg excipient: colloidal silicon dioxide glucose hyprolose hypromellose magnesium stearate maize starch poloxamer povidone propylene glycol purified talc titanium dioxide